Zobrazeno 1 - 5
of 5
pro vyhledávání: '"35"'
Autor:
William C. Wood, Fengmin Zhao, Vicky Jones, Silvana Martino, Nancy E. Davidson, Vered Stearns, Molin Wang, Tom Saphner, George W. Sledge, Joseph A. Sparano, Edith A. Perez, Bryan P. Schneider, Antonio C. Wolff
Publikováno v:
Journal of Clinical Oncology. 30:3051-3057
Purpose Neuropathy is a common and potentially disabling complication of adjuvant taxane therapy. Recent studies have identified candidate single nucleotide polymorphisms associated with taxane-induced neuropathy. Therefore, we sought to determine wh
Autor:
David Smith, Charles J. Ryan, Maha Hussain, Andrea L. Harzstark, Jeremy Sharib, Vivian Weinberg, Tomasz M. Beer, Paul Mathew, Eric J. Small, Jonathan E. Rosenberg, Lance C. Pagliaro, Christopher W. Ryan
Publikováno v:
Journal of Clinical Oncology. 27:2772-2778
Purpose Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed. Patients and
Autor:
Ana Lluch, Monica Fornier, David Lebwohl, Edgardo Rivera, Linda T. Vahdat, Patrice Viens, José Baselga, Eva Thomas, Valentina Guarneri, Valerie Poulart, Josep Tabernero, J. Klimovsky, Pierfranco Conte, Howard A. Burris, Miguel Martin, Craig A. Bunnell, Pierre Fumoleau
Publikováno v:
Journal of Clinical Oncology. 25:3399-3406
Purpose Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing apo
Autor:
Bipinkumar Amin, Dvorit Samid, Luis A. Meza, William J. Gradishar, Todd Hill, Yin Miao Chen, Elyse E. Lower, P. Kelly Marcom
Publikováno v:
Journal of Clinical Oncology. 22:2321-2327
Purpose The goal of this multicenter, open-label phase II study was the clinical evaluation of combination therapy with the oral fluoropyrimidine capecitabine and the taxane paclitaxel in patients with metastatic breast cancer (MBC). Patients and Met
Autor:
Francisco J. Esteva, Terry L. Smith, W. Fraser Symmans, Edgardo Rivera, Gabriel N. Hortobagyi, W. Joseph Thompson, Lajos Pusztai, James L. Murray, Kimberly M. Nealy, Vicente Valero, Jim Hou Zhen, Banu Arun, Daniel J. Booser, Amy Gibbs, Clark M. Whitehead
Publikováno v:
Journal of Clinical Oncology. 21:3454-3461
Purpose: We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC). Patients and Methods: All patients had received previous anthracycline and taxane chemotherapies. T